Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
EMERYVILLE, Calif., April 11, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, Gail Farfel, Ph.D., Executive Vice President and Chief Development Officer, and Michael P. Smith, Executive Vice President, Chief Financial Officer, Treasurer and Secretary, will provide a corporate update at the LEERINK Partners CNS Day, being held in New York City on April 18, 2018.
LEERINK Partners CNS Day – Zogenix Presentation Details
Date: Wednesday, April 18, 2018
Time: 2:40 pm Eastern Time / 11:40 am Pacific Time
Location: New York, NY - Convene Conference Center
The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at www.ir.zogenix.com.
About Zogenix
Zogenix, Inc. (NASDAQ:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors:
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987
[email protected]
